Wegovy Weight Loss Services in Newport Beach, CA
When the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021, it marked the most significant advance in obesity pharmacotherapy in decades. Two years later, the SELECT trial confirmed that semaglutide reduces the risk of serious cardiovascular events by 20 percent in overweight and obese adults — making Wegovy the only weight loss medication with proven cardiovascular mortality benefit. At Adonis Saremi, MD, Newport Beach patients access a physician-supervised Wegovy program built to fully leverage this medication’s extraordinary clinical profile.
What Makes Wegovy Clinically Different
Wegovy delivers semaglutide 2.4 mg via once-weekly subcutaneous injection — a dose specifically optimized for chronic weight management, higher than the 0.5 to 2 mg range used for diabetes. The STEP 1 trial showed 14.9 percent average weight loss versus 2.4 percent on placebo over 68 weeks. STEP 4 demonstrated that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their weight within a year — underscoring the importance of physician-planned maintenance.
The Evidence Behind Wegovy
- STEP 1 (2021) — 14.9 percent average weight loss versus 2.4 percent placebo over 68 weeks in non-diabetic patients
- SELECT trial (2023) — 20 percent reduction in major adverse cardiovascular events in overweight adults without diabetes
- STEP 4 — patients who stopped semaglutide at 20 weeks regained approximately 11.6 of 17.3 lost pounds within a year
- STEP 5 — 15.2 percent average weight loss sustained over 104 weeks, confirming long-term efficacy
Is Wegovy the Right Program for You in Newport Beach?
- Adults in Newport Beach with a BMI of 30-plus, or 27-plus with hypertension, dyslipidemia, or another qualifying condition, who want FDA-approved chronic weight management therapy
- Patients who have tried dietary and lifestyle interventions seriously without adequate results — ready for a pharmaceutical approach backed by landmark clinical evidence
- Individuals with elevated cardiovascular risk who want a weight loss medication with a proven mortality benefit — the SELECT trial distinction is clinically meaningful
- Those who want a Wegovy program actively managed with proper titration, lab monitoring, and dietary integration — not just a prescription and a monthly refill
- Patients across Newport Beach and Orange County looking for a physician who can contextualize Wegovy within their full health picture.
Our Wegovy Weight Loss Program in Newport Beach
Pre-Treatment Evaluation
Every patient begins with a comprehensive clinical evaluation — thyroid and pancreatic history, current medication review, full metabolic labs, and cardiovascular risk assessment. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Titration Protocol
Wegovy follows a structured titration schedule — 0.25 mg for four weeks, increasing at four-week intervals through 0.5, 1.0, 1.7, and reaching 2.4 mg maintenance at week 17. Dr. Adonis Saremi adjusts pace based on your individual tolerability — never rushing titration beyond what your body is ready for.
Nutritional and Behavioral Integration
Our Newport Beach Wegovy program pairs pharmacotherapy with physician-designed nutritional guidance — prioritizing adequate protein, micronutrient completeness, and glycemic stability — alongside behavioral coaching that converts medication-assisted loss into permanent metabolic change.
Maintenance Planning
STEP 4's data makes one thing unmistakable: maintaining results requires a planned strategy. Dr. Adonis Saremi builds a personalized maintenance protocol into every Newport Beach patient's program as they approach their weight loss target.
Why Choose Dr. Adonis Saremi, MD for Wegovy in Newport Beach?
The SELECT Trial Changes the Clinical Calculus
For Newport Beach patients with cardiovascular risk factors, Wegovy is not simply a weight loss medication — it is a cardiovascular intervention with FDA backing. Dr. Adonis Saremi’s Internal Medicine board certification means he evaluates this dimension with the clinical depth it warrants.
Start your Wegovy program in Newport Beach. Call (619) 736-1748 or book your consultation online today.
Frequently Asked Questions
How does Wegovy differ from Ozempic?
Both contain semaglutide, but Wegovy uses the higher 2.4 mg dose specifically approved for chronic weight management. Ozempic is approved for type 2 diabetes at doses up to 2 mg.
What results can I realistically expect?
The STEP trials showed average weight loss of 14.9 to 17.4 percent across patient populations. Individual outcomes depend on adherence, lifestyle factors, and baseline health status.
What happens if I stop taking Wegovy?
Weight regain is the expected clinical outcome without a transition strategy. Our program builds a structured maintenance phase into every patient’s plan from day one.